C
Aug 19 at 01:01 PM
Reuters reported MRNA more than doubled intraday, with the move intensified by roughly 13.5% short interest in the free float; ORTEX estimated short sellers were facing about $4.8 billion of mark-to-market losses. That means part of today’s price action is a short squeeze—but the underlying catalyst itself is real and unusually material. $Moderna(MRNA.US)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.